ClinicalTrials.gg
RecruitingNCT05984147ASHA-1Updated Apr 17, 2026

A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)

A Phase 1 interventional study of AUR108 in Relapsed Advanced Lymphomas, sponsored by Aurigene Discovery Technologies Limited. Recruiting at 27 sites in India. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Aurigene Discovery Technologies Limited (part of Dr. Reddy's Laboratories Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Study summary

An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced lymphomas will be done to assess AUR108 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.

Read the detailed description

This is a Phase I, Open Label, Dose-Escalation, First-in-Human study in adult patients with select relapsed advanced lymphomas. The safety and tolerability of oral AUR108 will be evaluated in patients with Non-Hodgkin lymphoma and Hodgkin lymphoma who do not have any available curative or life-prolonging treatment options and have exhausted all effective locally available therapies. The traditional 3+3 design for dose escalation will be used to evaluate the safety, pharmacokinetics/pharmacodynamics, and determine the Optimal Biological Dose of AUR108 as a single agent. The Optimal Biological Dose will be selected using a totality of safety, PK, and PD data.

02

Conditions studied

  • Relapsed Advanced Lymphomas

Keywords

  • Relapse Advanced Lymphomas
  • Diffuse large B-cell lymphoma
  • Follicular lymphoma
  • Mature T/NK-cell lymphomas
  • Other Hodgkin lymphoma
03

In context

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's planned enrollment of 40 is close to the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

Aurigene Discovery Technologies Limited is the lead sponsor of 12 studies on the registry; 4 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 1 (13%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females ≥ 18 years of age
  2. (ECOG) Performance status of 0 or 1
  3. Acceptable bone marrow and organ function at screening as described below:

    1. ≥ 1000/μL (without WBC growth factor support)
    2. count ≥ 75,000/μL without transfusion support
    3. ≥ 9 g/dL (Transfusion is allowed to achieve this Hb)
    4. Total ≤ 1.5 x ; (Patients with known Gilbert's syndrome are allowed with a Total Bilirubin ≤ 2.5 x ULN)
    5. (SGOT) ≤ 3 x ULN (≤ 5 × ULN if known liver )
    6. ALT (SGPT) ≤ 3 x ULN (≤ 5 × ULN if known liver metastases)
    7. (CrCl) ≥ 30 mL/min (either measured or estimated by the Cockcroft-Gault formula). (Cockcroft-Gault formula for estimated creatinine clearance [eCrCl]: eCrCl = [140- Age] × Weight [kg] × [0.85 if Female] / [72 × serum creatinine (mg/dL)]).
  4. Ability to swallow and retain oral medications
  5. Histo-pathological diagnosis of a Non-Hodgkin lymphoma orHodgkin Lymphoma. Note: The lymphoma should be either in Stage III or IV according to Lugano classification (Cheson BD et al, 2014) at screening.
  6. In the case of subjects who have lymphoma for which high-dose chemotherapy and stem cell transplantation (HDASCT) is considered a standard curative therapy, eligibility for this study requires that the subject's disease has after HDASCT, that the subject is not eligible for HD-ASCT, or that the subject has refused HD-ASCT.
  7. In the case of subjects who have lymphoma for which CAR-T therapy is considered a standard therapy, eligibility for this study requires that the subjects disease has relapsed after CAR-T, or that the subject has refused CAR-T, or that the CAR-T therapy is not accessible to the patient.
  8. Evidence of as per Lugano Criteria for Lymphoma (Cheson BD et al, 2014).
  9. Standard curative measures do not exist, and patient must have exhausted all effective therapies, available locally.

    1. At a minimum, the patients must have received at least 2 . These systemic therapies could be either in the stage II, III or IV.
    2. Any cancer patient with access to any effective therapy must not be enrolled.

Exclusion criteria

Exclusion Criteria:

  1. Systemic anti-cancer therapy, such as chemotherapy, or biological therapy, immunomodulatory drug therapy, received within the past 28 days or 5 half-lives, whichever is longer, from the Cycle 1 Day 1 of the study.

    Note: Concomitant use of low dose prednisone (up to 10 mg/day) is allowed.

  2. Presence of an acute or chronic toxicity resulting from prior anticancer treatment, with the exception of alopecia or nail changes, that has not resolved to Grade ≤ 1, as determined by v 5.0.
  3. Definitive Radiotherapy within the last 21 days of Cycle 1 Day 1 (limited field palliative radiation is allowed and no restrictions during the screening period or during the trial).
  4. Use of any agent within 28 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
  5. Patients with cutaneous lymphomas, mycosis fungoides (MF) or Sézary syndrome (SS).
  6. Primary CNS lymphoma
  7. Known symptomatic or untreated or recently treated (≤ 6 months of screening) central nervous system (CNS) lymphoma. Patients with previously treated (> 6 months of screening) CNS lymphoma and are now stable and asymptomatic, from CNS perspective, are allowed
  8. Patients with lymphoma that requires immediate cytoreductive therapy
  9. Patients with lymphoma that requires immediate cytoreductive therapy
  10. Patients on the drugs which are sensitive substrates of CYP2C8 and cannot be discontinued at least one week prior to Cycle 1 Day 1
  11. Patients on the drugs which are sensitive substrates of either Poglycoprotein (P-gp) or breast cancer resistance protein (BCRP) and cannot be discontinued at least one week prior to Cycle 1 Day 1
  12. Major surgery ≤ 28 days from Cycle 1 Day 1 (major surgery is defined as a procedure requiring general anesthesia)
  13. Active infection requiring systemic therapy. Note: Prophylactic use of antibiotics is allowed. Any infection detected during screening period which is resolved adequately according to investigator before the Cycle 1 Day 1, is allowed.
  14. Known to be (HIV) positive or have an acquired immunodeficiency syndrome-related illness
  15. Known active or chronic (HbsAg +ve) or infection (HCV antibody +ve)
  16. The patient who is expected to require any other form of antineoplastic therapy or targeted therapy while on study.
  17. Uncontrolled congestive heart failure ( (NYHA) Class 2-4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, or , or pulmonary embolism within 3 months prior to Cycle 1 Day 1
  18. Ongoing cardiac dysrhythmias requiring treatment of any grade or treatment of cardiac dysrhythmias in past 3 months, before Cycle 1 Day 1.
  19. (Bazzett) interval >460 ms on at screening and/or at Cycle 1 Day 1 pre-dose.
  20. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or significant gastritis, active bleeding diatheses, presence of any major medical illness (e.g. renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or psychiatric illness/social situations or laboratory / ECG abnormalities at screening, any or a combination of illnesses, which, in the opinion of the PI, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study
  21. Current swab-positive or suspected (under investigation) Covid-19 infection or fever and other signs or symptoms suggestive of Covid-19 infection with recent contact of person(s) with confirmed Covid-19 infection, at screening or Cycle 1 Day 1.
  22. History of another primary within 5 years prior to starting study drug, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study.
  23. Positive pregnancy test for women of (WOCBP) at the screening or enrolment visit
  24. Lactating women or WOCBP who are neither surgically sterilized nor willing to use reliable methods (hormonal contraceptive, IUD, or any double combination of male or female condom, spermicidal gel, diaphragm, sponge, cervical cap).
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    AUR108, 50mg to 300mg

    Currently, planned dose levels are 50,90,150,220,300 mg will be administered in 3+/4- regimen.

    Drug: AUR108

Interventions

  • DrugAUR108

    3 Days dosing, and 4 days no dose in a week

06

What researchers measure

Primary outcomes

  1. 1. First cycle Dose Limiting Toxicities (DLT)

    Assess dose limiliting toxicities of AUR108

    Time frame: 28 Days

  2. Safety of AUR108 as measured by the number of participants with treatment-related adverse events (AE) graded according to NCI CTCAE version 5.0

    Number of participants with TEAEs

    Time frame: Through study completion, an average of 1 year

  3. Pharmacokinetics Maximum Concentration (Cmax)

    Maximum Concentration of AUR108

    Time frame: Day 1 and Day 17

  4. Pharmacokinetics: Time to Maximum concentration (Tmax)

    Tmax in hours

    Time frame: Day 1 and Day 17

  5. Pharmacokinetics: Area under the curve (AUC)

    Area under the curve (AUC) of AUR108 in h\* ng/mL

    Time frame: Day 1 and Day 17

  6. Pharmacokinetics: Terminal elimination half-life

    Terminal elimination half-life of AUR 108 in hours

    Time frame: Day 17

  7. Maximum concentration (Cmax) administered under fasting/fed condition

    Compare in fast and fed conditions

    Time frame: Day 8

  8. Time to Maximum concentration (Tmax) administered under fasting/fed condition

    Compare Tmax in fast and fed conditions

    Time frame: Day 8

  9. Area under curve (AUC) administered under fasting/fed condition

    Compare AUC in fast and fed conditions

    Time frame: Day 8

Other outcomes

  1. PD biomarker assessment

    Change from baseline in biomarker (DHO) levels

    Time frame: Day 1, Day 2, Day 17 and Day 18

  2. Overall Response Rate

    Efficacy assessments by Overall Response Rate

    Time frame: Through study completion, an average of 1 year

  3. Duration of Response

    Efficacy assessments by Duration of Response

    Time frame: Through study completion, an average of 1 year

  4. Progression Free Survival

    Efficacy assessments by Progression Free Survival (PFS)

    Time frame: Through study completion, an average of 1 year

07

Study locations

27 of 27 sites recruiting
  • Omega Cancer Hospitals
    Visakhapatnam, Andhra Pradesh 530040, India
    Recruiting
  • Post Graduate Institute of Medical Education & Research,
    Chandigarh, Chandigarh 160012, India
    Recruiting
  • Cellcure Care Cancer Pvt Ltd
    Ahmedabad, Gujarat 380009, India
    Recruiting
    • Dr Sandip Shah, MBBS,MD · Contactsandip60@yahoo.com · 9824041170
    • Dr Sandip Shah, MBBS,MD · Principal investigator
  • HCC Happiness Care and Cure Multispeciality Hospital
    Ahmedabad, Gujarat 380015, India
    Recruiting
  • Shankus Hospital Pvt. Ltd.
    Ahmedabad, Gujarat 384110, India
    Recruiting
    • Dr Nirali Trivedi, MBBS,MD · Contactdrgbiswas@gmail.com · 9937500878
    • Dr Niral Trivedi, MBBS,MD · Principal investigator
  • Unique Hospital
    Surat, Gujarat 395002, India
    Recruiting
  • Kiran Multi Speciality Hospital
    Surat, Gujarat 395004, India
    Recruiting
  • Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences
    Rohtak, Haryana 124001, India
    Recruiting
    • Dr Sudhir Atri, MBBS,DM · Contactssmantri74@yahoo.com · 9315895272
    • Dr Sudhir Atri, MBBS,DM · Principal investigator
  • Super Specialty Hospital (G.M.C) Srinagar
    Srinagar, Jammu and Kashmir 190010, India
    Recruiting
  • KLES Dr Prabhakar Kore Hospital and MRC
    Belagavi, Karnataka 590010, India
    Recruiting
  • Amrita Institute of Medical Sciences (AIMS)
    Kochi, Kerala 682041, India
    Recruiting
  • Sujan Surgical Cancer Hospital and Amravati Cancer Foundation
    Amravati, Maharashtra 444606, India
    Recruiting
  • Dr. Bafna's Star Superspeciality Clinic & Hospital
    Kolhāpur, Maharashtra 416005, India
    Recruiting
    • Dr Varun Bafna, DNB (Hematology) · Contactdrvarunbafna6@gmail.com · 9066565353
    • Dr Varun Bafna, DNB (Hematology) · Principal investigator
  • Kolhapur Cancer Centre
    Kolhāpur, Maharashtra 416234, India
    Recruiting
  • Mumbai Onco Care Centre
    Mumbai, Maharashtra 400056, India
    Recruiting
  • All India Institute of Medical Sciences
    Nagpur, Maharashtra 441108, India
    Recruiting
  • HCG Manavata Cancer Centre
    Nashik, Maharashtra 422002, India
    Recruiting
  • Deenanath Mangeshkar Hospital & Research Center
    Pune, Maharashtra 411004, India
    Recruiting
  • Sahyadri Super Specialty Hospital
    Pune, Maharashtra 411006, India
    Recruiting
    • Dr Shashikant Apte, MBBS,MD · Contactshashikant.apte@gmail.com · 9822404983
    • Dr Shashikant Apte, MBBS,MD · Principal investigator
  • Sushrut Hospital
    Pune, Maharashtra 411038, India
    Recruiting
  • Armed Forces Medical College
    Pune, Maharashtra 41140, India
    Recruiting
    • Dr Uday Yanamandra, MBBS,MD · Contactudayj2@gmail.com · 8195035551
    • Dr Uday Yanamandra, MBBS,MD · Principal investigator
  • Sunact Cancer Institute Pvt. Ltd
    Thane, Maharashtra 400615, India
    Recruiting
    • Dr Ashay Karpe, MBBS · Contactashayoncology@gmail.com · 9029083054
    • Dr Ashay Karpe, MBBS · Principal investigator
  • Rajiv Gandhi Cancer Institute and Research Centre
    Delhi, National Capital Territory of Delhi 110085, India
    Recruiting
  • All India Institute of Medical Sciences
    Delhi, New Delhi 10029, India
    Recruiting
  • Sparsh Hospital and Critical Care (P) Ltd.
    Bhubaneswar, Odisha 751007, India
    Recruiting
  • MNJ Institute of Oncology & Regional Cancer Centre
    Hyderabad, Telangana 500004, India
    Recruiting
  • Tata Medical Center
    Kolkata, West Bengal 700160, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Aug 2027, 46 months after the start.

Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 71. This study's planned 46 months is close to that.

Counting every sponsor, half of 195 studies reached it within 53 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2023
First posted
Aug 9, 2023
StartActual
Oct 19, 2023
Primary completionEst.
Aug 30, 2027
CompletionEst.
Aug 30, 2027
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05984147
Responsible party
Sponsor
First posted
Aug 9, 2023
Start date
Oct 19, 2023
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Apr 17, 2026

Study contacts

Suchit Kumbhare
Contact
suchit_k@aurigene.com
+918104730078
Suresh Oduru
Contact
suresh_o@aurigene.com
9866225593
Akhil Kumar
principal investigator · Chief Medical Officer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion